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VAN DIE REDAKSIE
Storm in a Teacup?
The United States Food and Drug Administration
seems to stumble from one premature announce-
ment to another in the field of diabetes mellitus.
First they caused the drug firms to include in the
notices with each package of any sulphonylurea
that these drugs were contraindicated during preg-
nancy, and even in women of childbearing age,
which we know in this country to be nonsense.
Only a year or so ago they caused cyclamate
sweeteners to be banned on totally inadequate
evidence, and now they urge that tolbutamide and
other oral antidiabetic agents are to be used by
doctors only as a last resort in maturity-onset
diabetics. This recommendation, endorsed by the
Council of the American Diabetes Association, has
apparently caused alarm and despondency among
the estimated 1 million Americans who were taking
tolbutamide and has thrown practising physicians
into a tizzy, making them scared to use oral agents
in case a court action is brought against them
should their patient develop myocardial infarct
while on the drug.
The study that caused all the fuss was conducted
at 12 University medical centres.' Patients were
mild, non-insulin dependent, recently diagnosed,
maturity-onset type diabetics and were divided
randomly into 4 treatment groups, each containing
approximately 200 subjects, as follows: diet plus
placebo, diet plus tolbutamide (1'5 g daily), diet
plus fixed dose of insulin (10 - 16 units according to
body surface area) and diet plus insulin according
to need. Patients were maintained on these sche-
dules and followed up for 5 - 8V2 years. A fifth,
phenformin-treated group, was added later but does
not enter into the crucial analysis,
Analysis after 8% years revealed 26 deaths from
cardiovascular causes in the tolbutamide group, 10
in the placebo and 13 and 12 in the 2 insulin groups.
The Chi-square test of significance for the tolbuta-
mide-placebo comparison yielded a P value of
0'005. There is considerable doubt, however,
whether such statistical tests are valid in view of
various baseline and inter-clinic discrepancies. The
subjects were socially and ethnically heterogenous,
the excess number of deaths in the tolbutamide
group emanated from 3 clinics only, patients who
discontinued or changed treatment were included
with their original groups, and during the last year
or so the difference in vascular deaths was no
longer evident. Further, the' 5 chief cardiovascular
'risk factors' were all more frequent initially in the
tolbutamide-treated group than in the placebo
group as follows: ECG abnormality 4% against
3% (astonishingly low), use of digitalis 7-6% against
4-5%, arterial calcification 19'7% against 14-3%,
angina pectoris 7'0% against 5-0%, serum choles-
terol > 300 mg/ 100 ml 15'1 % against 8'6%. There
was, however, less hypertension in the tolbuta-
mide group.
The total death rates were not significantly dif-
ferent between the 4 groups, in fact there were
fewer deaths from cancer in the tolbutamide group
than in the placebo group-a difference which
might be claimed as being 'significant'2-so that
tolbutamide might even be considered beneficial
in 'preventing' cancer.
Regarding the design of the trial, an outstanding
error seems to us to be the use of a fixed dose
of 1'5 g of tolbutamide for so many people
throughout the whole study without reference to
control of the diabetes or even apparently of
symptoms. Since we know that tolbutamide fails
initially to benefit some 30% of maturity-onset
diabetics, and that the secondary failure rate at
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the end of 5 years is around 50%,3 such an empi-
rical method of using tolbutamide appears to have
little relation to clinical practice. (The same would
seem to apply to the 10 - 16 units of insulin, given
on fixed dose according to surface area-a new
trial of homoeopathy, evidently.) Hence the lack of
benefit to diabetics on this tolbutamide schedule,
which is emphasized in the UGDP report, is hardly
surprising to those of us who believe in at least
reasonable control of the diabetic state.
Further criticism has been made of the change
in definitions adopted by the study group between
their initial report in 1968 and their final report in
1970!,5 In particular, originally 25% of the tolbuta-
mide group were noted as having at least one
major ECG abnormality at the time of entry to the
trial, as against 15% of the placebo group. Yet in
the 1970 report only 4% of the tolbutamide and
3% of the placebo group had major ECG abnor-
malities.
It is impossible to ensure perfection in important
large-scale trials of this sort and it is always easy
to point out errors after the event. There is no
question that the physicians concerned in the trial
acted in good faith and to the best of their ability.
It seems to us, however, that their continued re-
liance on inadequate data and their refusal to admit
the possibility of error 'are not in accordance with
the best scientific ethics. Furthermo're, it is difficult
not to condemn the premature announcement and
recommendations from both the FDA and the
Committee of the American Diabetes Association,
especially in their blanket condemnation of all oral
drugs, without a shred of evidence against any but
tolbutamide. At least it is pleasing to note that no
other country appears to have been equally preci-
pitate, and official recommendations for patients
to continue oral drugs have been promulgated in
several.
We must keep an open mind. Further work may
indicate a true danger from tolbutamide and doctors
must of course follow their own beliefs-any who
believe that the dangers have been proved and
that they exceed the benefits, will stop prescribing
tolbutamide.
It is relevant to mention other studies that indi-
cate either no danger from tolbutamide or even
improvement in cardiovascular status. From the
Bedford Survey, 248 'borderline' diabetics were
randomly allocated to 4 different treatment sche-
dules." Analysis after 7 years revealed that fewer
'new arterial events' had occurred in the tolbuta-
mide groups than in the placebo group. In Stock-
holm a 4-year study was made on 270 patients
discharged from hospital after their first myocardial
infarction. 7 Half were given tolbutamide and half
placebo irrespective of the glucose tolerance.
During the first 18 months the mortality was signi-
ficantly lower in the tolbutamide group, though
there was less difference by the end of the study.
The glucose tolerance of the tolbutamide-treated
group improved significantly when retested after
the drug had been withheld for 60 hours. This inves-
tigation is worth careful study. In the Framingham
study oral agents did not appear to differ from
other modes of treatment with regard to incidence
of cardiovascular disease,s and retrospective stu-
dies from the Joslin Clinic indicated no difference.9
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